To evaluate the contribution of association studies of candidate polymorphisms to inherited predisposition to Hodgkin lymphoma (HL), we conducted a systematic review and meta-analysis of published case-control studies. Of the variants examined more than once in candidate gene association studies, we identified 21 studies that reported on 12 polymorphic variants in 10 genes. Data were also extracted from a published genome wide association study to allow analysis of an additional 47 variants in a further 30 genes. Promising associations were seen in nine of the variants (p < 0.05). Given that the estimated false positive report probabilities (FPRPs) for all associations are high (i.e. FPRP > 0.2), these findings should be interpreted with caution. While studies of candidate polymorphisms may be an attractive means of identifying risk factors for HL, future studies should employ sample sizes adequately powered to identify variants having only modest effects on HL risk. Furthermore, because of aetiological heterogeneity within HL, stratification of genotyping according to age, tumour Epstein-Barr virus status and histology is essential.
Introduction
Hodgkin lymphoma (HL) is a B-cell malignancy affecting approximately 3 per 100 000 of the population each year in most Western countries [1] . HL is typically classified based on histopathological appearances into classical HL, which accounts for 95% of cases, and nodular lymphocyte predominant HL. The presence of Epstein-Barr virus (EBV) latent membrane protein and/or EBV-encoded small RNAs in Hodgkin Reed-Sternberg cells defines EBV-positive disease [2] .
HL shows a bimodal age distribution in incidence, with geographic specific differences. In economically developed countries, the first peak of incidence typically occurs around 20 years of age with a second peak around 65 years of age [1] . Evidence for the existence of inherited genetic predisposition to HL is derived from the high concordance rates in identical twins [3] and from case-control studies and cohort studies, which have shown a threefold increased risk of HL in relatives of HL patients [4] .
The failure to identify a major disease-causing locus has led to the proposal that a significant component of the inherited susceptibility is enshrined in the co-inheritance of multiple risk alleles, some of which are likely to be common. The most frequent method for identifying prevalent low risk variants is through association studies based on comparing the frequency of polymorphic genotypes in cases and controls. Alleles positively associated with the disease are analogous to risk factors in epidemiology and may be causally related to disease risk or be in linkage disequilibrium (LD) with disease-causing variants. There are a number of different methods of analysing the risk associated with a specific variant. For simple bi-allelic polymorphisms, the odds ratio (OR) of a disease can be derived by comparing allele frequencies in cases and controls. Alternatively, a comparison of frequencies of the three genotypes among cases and controls can be made, using homozygosity of the 'wild-type allele' as the reference group. Where homozygotes are rare, heterozygotes and homozygotes are grouped together, but this is only appropriate if a dominant model of disease susceptibility can be assumed. Similarly, combining heterozygotes with wild-type homozygotes is only appropriate if alleles act recessively.
The genetic candidates that have been evaluated as susceptibility genes for HL to date can be divided into the following groups: immune function/response, carcinogen metabolism enzymes, folate metabolism enzymes, DNA repair proteins, and others (Table 1) . We elected to 35 Meta-analysis of candidate gene association studies and risk of HL exclude candidate gene association studies exploring the human leucocyte antigen (HLA) region and HL given the already established predisposition at the HLA region [5] and the complex LD structure making identification of the disease-causing variant problematic.
Although some polymorphic variants have only been examined once, most have been evaluated as risk factors in several studies but often with discordant findings. Furthermore, many of the studies have been based on small sample sizes with limited power to robustly demonstrate a relationship with HL risk. To gain better insight into the impact of polymorphic variants on the risk of HL, we have undertaken a systematic review of published studies and used standard meta-analysis techniques according to Cochrane [6] . In addition, we have used genotype data from a published Genome-Wide Association Study (GWAS) to perform a meta-analysis on variants that have only been examined once in the literature [7, 8] .
Methods

Study identification
A literature search for studies reporting on the association between polymorphic variants and HL was conducted using the electronic database PubMed from May 1991 to December 2014. The search strategy included using the keywords 'Hodgkin lymphoma', 'case', 'control', 'polymorphism', 'risk', 'genetic', and 'association'. We searched for additional studies in the bibliographies of identified publications, including previous review articles and meta-analyses [9, 10] .
Selection criteria
Studies were eligible if they were based on unrelated individuals and examined the association between HL and variants in candidate genes chosen based on a priori knowledge of HL/cancer biology. Variants were only carried forward for meta-analysis if full genotype data for both cases and controls were extractable from the article. Only studies published as full-length articles or letters in peerreviewed journals in English were included in the analysis.
Data extraction
Data for analyses, including study design, sample size and ethnicity as well as allele and genotype frequencies, were extracted from the published articles and summarized in a consistent manner to aid comparison.
Data extraction from genome wide association studies
Where possible, genotype data from 1465 cases and 6417 controls were extracted from published GWAS to allow the inclusion of variants examined once in the literature [7, 8] .
Statistical analysis
Raw data for genotype frequencies, without adjustment, were used for calculation of the study-specific estimates of OR and 95% confidence limits (CIs). Cochran's Q-statistic was used to test for heterogeneity, and the percentage variability of the pooled OR attributable to heterogeneity between studies was quantified using the I 2 statistic (large heterogeneity typically defined by I 2 > 75%). A p-value > 0.05 for the Q test was considered to indicate a lack of heterogeneity across studies, so the pooled estimation of the OR of each study was calculated by the fixed effects model [11] . Otherwise, the random effects model was employed [12] . The significance of the pooled OR was determined by the Z-test and p < 0.05 was considered as statistically significant. An estimate of the potential publication bias was conducted by the examination of funnel plots, in which the standard error (SE) of log(OR) of each study was plotted against its log(OR). An asymmetric plot is reflective of publication bias. The funnel plot symmetry was assessed by Egger's test based on inverse-variance weighted regression of the effect sizes on their precision (the inverse of standard error), to test whether the intercept deviated significantly from zero; a p < 0.05 was considered indicative of statistically significant publication bias [13] .
To test for population stratification (i.e. deviation from Hardy-Weinberg equilibrium (HWE)), the distribution of genotypes in control subjects of each individual population was tested for departure by means of the χ 2 test [14] . For each statistically significant association identified, we estimated the false positive reporting probability (FPRP) [15] . The FPRP value is determined by the p-value, the prior probability for the association and statistical power. We calculated FPRP assuming a prior probability of 0.001 proposed for candidate gene analyses [16] . Statistical power was based on the ability to detect an OR of 1.2 and 1.5 (or reciprocal), with α equal to the observed p-value. To evaluate whether the association was noteworthy, we imposed a FPRP cut-off value of 0.2, advocated for summary analyses. Hence, FPRP values < 0.2 were considered to indicate robust associations [15] .
Statistical analyses were undertaken using STATA version 10.0 (Stata Corporation, College Station, TX).
Results
Characteristics of published studies
Meta-analysis of variants studies more than once in the literature
We retrieved 84 published studies using our search criteria ( Figure 1 ). Of variants examined more than once in the literature, we identified a total of 21 publications detailing 13 variants in 10 genes ( Table 1) . Six of the variants were genotyped in the published GWAS. All of the published studies were essentially of similar design, although different types of controls were analysed ( Table 2 ). In the final group, six studies included data on ethnicity of cases and controls [17] [18] [19] [20] [21] , three studies included data on EBVstatus [17, 22, 23] and eight studies included data on histopathological subtype of HL [17, 19, 20, 22, [24] [25] [26] [27] . Two studies stratified genotype by histology [23, 25] , and two 
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Immune response genes
One of the two studies that examined the association between IL-10 rs1800890 and HL demonstrated a lower risk of HL for those >40 years with homozygosity or carrier status of the T allele [24] . The departure of genotype frequencies from HWE (p HWE = 0.02) in the control group however suggests population stratification in this study. Pooling data from both studies failed to demonstrate a significant association between the variant and HL risk (Table 4) [24, 34] . In addition, there was no evidence of an association when pooling together three studies investigating the IL-10 variant, rs1800896 nor with the inclusion of data from the GWAS (Table 4) [7, 8, 24, 25, 35] .
Two studies have evaluated rs1800795, a single nucleotide polymorphism (SNP) located upstream of IL-6 [21, 23] . One study utilized monozygotic and dizygotic twins with at least one affected twin. When all cases were analysed, homozygosity of the C allele appeared to be protective for HL and this was identified in the NS subgroup [21] . These findings were not, however, supported by a larger analysis of unrelated patients with HL nor in the pooled analysis [23] (Table 4 ).
Carcinogen metabolism genes
Four studies have investigated the SNP rs1696 in GSTP1 and risk of developing HL [18, 24, 36, 30] . One study found a protective effect of the heterozygous (AG) genotype [24] , while another study found the wild type genotype (AA) to be associated with an increased risk of HL [18] and a third study found the less prevalent genotype (GG) to be associated with an increased risk of HL [36] (Table 3) . Two studies demonstrated evidence of population stratification with departure from HWE in the controls (p HWE = 0.01). No evidence of association was found when these studies were pooled nor with the inclusion of data from the GWAS (Table 4) .
Six studies have investigated deletion of the GSTT1 gene and predisposition to HL. GSTT1 deletion conferred an increased risk of HL in three studies [24, 27, 29] and no effect in three studies [18, 36, 30] (Table 3) . Pooling data from the six studies revealed no evidence of association of GSTT1 deletion with HL risk (Table 4) .
Seven studies have examined GSTM1 deletion and risk of developing HL [18, 24, 26, 36, 30, 29, 38] . Neither the studies nor a pooled analysis provides evidence for an association between GSTM1 deletion and HL risk (Tables 3 and 4) . 
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DNA repair genes
Two studies have examined the risk of HL and the SNP rs17655 in XPG/ERCC5 [19, 28] , neither demonstrating an association between genotype and HL risk (Table 3) . However, in a pooled analysis, a significant association between XPG/ERCC5, rs17655 CC homozygosity and an increased risk of developing HL with an OR = 2.03 (95% CI [1.01, 4.06], p = 0.046) was found (Figure 2) . Furthermore, with the addition of data from GWAS, the association appeared promising at 1.68 (95% CI [1.18, 2.37], p = 0.01) (Figure 2 and Table 4 ). There was no evidence of small study effect (Figure 3 ).
Folate metabolism genes
Four studies have evaluated the risk of HL with rs1801133, in MTHFR [17, 32, 37, 33] . In isolation, none of the studies provided evidence for an association between the genotype and risk ( (Table 4) . Two studies have evaluated the risk of HL with rs1805087 in MTR [17, 28] . Neither demonstrated an association (Table 3) . Similarly, no association was shown in a meta-analysis that included GWAS data (Table 4) .
Other genes
Three studies have investigated the role of rs20417 in COX2 and HL risk [20, 22, 31] . One study demonstrated an association with both carrier and homozygous minor genotype [20] (Table 3) . However, in a pooled analysis with the inclusion of data from GWAS, no association was observed (Table 4) . Two studies have also examined the risk of HL rs689466 in COX2, but no association was identified (Table 4) [22, 31] .
Finally, two studies have investigated the tandem repeat in UGT1A1 and HL risk. No significant association was seen in either study (Table 3) . A pooled analysis did not provide evidence for a relationship between UGT1A1 genotype and HL (Table 4) [24, 30] . Begg's funnel plot (using odds ratio (OR) of Hodgkin lymphoma risk associated with variant genotype rs17655 CC versus GG). The horizontal line represents the meta-analysis summary estimate, and the diagonal lines pseudo-95% CI limits about the effect estimate. In the absence of publication bias, studies will be distributed symmetrically above and below the horizontal line. Asymmetry on the top of the graph indicates evidence of publication bias towards studies reporting a positive logOR. LogOR, natural logarithm of the OR; s.e. of logOR, standard error of the logOR 
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Variants examined once in published studies
Using directly typed SNPs from the GWAS, we were able to include an additional 47 variants published in eight papers [39] [40] [41] [42] [43] [44] [45] [46] . There was evidence for association in eight of these variants (p < 0.05).
False positive report probability
To evaluate the robustness of the three significant findings from the pooled analyses, we calculated FPRP conditional on a prior probability of 0.001. None of the aforementioned results are considered noteworthy on the basis of the pre-defined assumptions (Tables 4 and 5 ). For example, although the summary OR from the pooled analysis of rs17655 indicated a statistically significant positive association with risk, the FPRP was 0.99, which is much higher than the conventionally accepted threshold cut-off for noteworthiness of <0.2.
Discussion
It is clear that substantial research has been carried out examining polymorphic variants in a number of putative candidate genes as risk factors for HL. While our metaanalysis provides some support for eight different variants as risk factors for HL (rs1800587, rs16944, rs1801275, rs2229113, rs1057910, rs1799853, rs3212986, rs696), these data should be interpreted with caution as the identified associations are not robust on the basis of multiple testing correction and FPRP. Even excluding this, a number of general conclusions can be constructed from the published studies. Few of the studied variants have been reported as statistically significant in more than one study. It is generally acknowledged that independent replication of study findings is necessary to assess the robustness of potential associations. In some studies, the failure to demonstrate a relationship may simply be a consequence of poor power because of sample size. GWAS of cancer have revealed that the relative risk associated with common variants is typically between 1.1 and 1.3 [47] . Fewer than 40% of the studies we reviewed had 80% power to demonstrate even a twofold difference in risk at the 0.05 significance level. To overcome this lack of power, we have undertaken a meta-analysis, pooling the data from the published studies. There are, however, caveats to this statistical procedure.
In any systematic review, publication bias is clearly of great concern. The most common scenario is that negative findings may go unreported. Furthermore, many studies excluded do not describe the ethnicity of cases or controls, and it is assumed that each polymorphism is functional with respect to risk in each study population. If, however, the polymorphism is a neutral marker for another variant, the assumption may well not apply, because LD is often population-dependent. Here we have relied on data extractable from published reports. Ideally, access to primary data is desirable; in the absence of this, it would be advisable that in the future summary data be published to allow metaanalysis to be conducted. An important lesson from the published studies is that greater attention should be paid to study design. Data from GWAS have demonstrated a differing allelic architecture of genetic susceptibility to HL with respect to histology and EBV status. Few studies have stratified genotype data according to age, histology and EBV status. This may explain the lack of consistency in candidate gene association studies and in our meta-analysis. Because of the lack of stratification in the majority of studies, we were unable to include this in our meta-analysis. The issue of population stratification in case-control studies and resulting false positive results is also of concern. Such associations occur because of population subdivision and non-random mating, leading to variation in the marker frequency within the population as a result of founder effects and/or genetic drift. The severity of spurious association becomes an increasing problem with increasing study size. To avoid this problem, potential confounding effect of population stratification should be allowed for in the design and analysis of the study. This requires the identification of sub-populations in terms of factors that can influence both disease and marker allele frequencies. Provided cases and controls are well matched, differences in the frequency of genotypes will only be seen at predisposition loci. Hence, stratification can be detected by typing a series of unlinked markers chosen from a panel known to exhibit differences in allele frequency between populations.
We have attempted to review published analyses of the relationship between polymorphic variation and risk of HL through several iterations of search criteria; it is possible, however, that we have missed some published studies. As the number of articles on genetic variation on risk of HL published in the past decade has increased considerably and continues to grow, we accept that this review provides a snapshot of progress to date in the field.
All of the studies we have reviewed have been based on a candidate gene approach. It is clear from studies of cancer that without a clear understanding of tumour causalities the definition of what constitutes a candidate gene is inherently problematic, making an unbiased approach through GWAS highly desirable. Moreover, the possibility of missing the identification of important variants in hitherto unstudied genes is avoided. Thus far, GWAS of HL have provided evidence that variation in a number of genes including REL, EOMES, ERAP1, IL13, PVT1, GATA3 and TCF3 [7, 8, 48, 49] influences the risk of developing HL. In contrast to the candidate gene studies, the substantial evidence supporting these variants, including sizeable power and replication in large samples, indicates that the associations are highly robust. These data thus provide the first unambiguous evidence that common low penetrance susceptibility alleles contribute to the risk of HL.
Conclusions
The search for polymorphic variants influencing the risk of HL is a worthy enterprise. However, the studies that have been conducted to date have important lessons for the design and execution of future studies. Candidate gene analyses should be viewed as complementary to GWAS, as they theoretically offer advantages both in terms of statistical power and an ability to identify low frequency risk variants. Furthermore, many functional variants, such as the small-scale insertion and deletions in carcinogen metabolism genes, are poorly captured by tagging SNPs used in GWAS. It is however clear that in addition to conducting studies using adequate sample, attention should be paid to study design to avoid problems of aetiological heterogeneity, population stratification and other sources of potential bias in order to maximize the output of any future candidate gene study.
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